|  |  |  |  |
| --- | --- | --- | --- |
| **Cancer Type** | **Therapy Targets** | **Drug Class** | **Drugs** |
| Colorectal cancer (CRC) | EGFR    BRAF    VEGF      PD-1    NTRK | EGFR antagonists    BRAF antagonists    VEGF antagonists      PD-1 antagonist    NTRK inhibitors | cetuximab, panitumumab    encorafenib + cetuximab    bevacizumab, ramucirumab, regorafenib, ziv-aflibercept    pembrolizumab, nivolumab    larotrectinib, entrectinib |
| Lung cancer (LCA; includes both small cell and non-small cell lung cancer) | ALK      ROS1    EGFR      PD-L1    BRAF    PD-1    CTLA-4    VEGF    NTRK | ALK antagonists      ROS1 antagonist    EGFR antagonists      PD-L1 antagonists    BRAF antagonist    PD-1 antagonists    CTLA-4 antagonist    VEGF antagonist    NTRK inhibitors | alectinib, brigatinib, ceritinib, crizotinib, lorlatinib    crizotinib, entrectinib    afatinib, erlotinib, gefitinib, osimertinib, dacomitinib    atezolizumab, durvalumab    dabrafenib + trametinib    pembrolizumab, nivolumab, cemiplimab    ipilimumab    ramucirumab    larotrectinib, entrectinib |
| Prostate cancer (PCA) | Androgen R      HRR    NTRK    --- | Androgen antagonists      PARP inhibitors    NTRK inhibitors    --- | abiraterone, apalutamide, enzalutamide, darolutamide    olaparib, rucaparib    larotrectinib, entrectinib    docetaxel, cabazitaxel |
| Gastroesophageal cancer (GEC) | HER-2    VEGF    PD-1    NTRK | HER-2 antagonist    VEGF antagonist    PD-1 antagonists    NTRK inhibitors | trastuzumab    ramucirumab    pembrolizumab, nivolumab    larotrectinib, entrectinib |
| Melanoma (MEL) | BRAF      CTLA-4    PD-L1    PD-1    MEK    NTRK | BRAF antagonists      CTLA-4 antagonist    PD-L1 antagonists    PD-1 antagonists    MEK inhibitor    NTRK inhibitors | dabrafenib, vemurafenib, encorafenib + binimetinib    ipilimumab    atezolizumab    pembrolizumab, nivolumab    cobimetinib    larotrectinib, entrectinib |
| Acute myeloid leukemia (AML) | FLT3    IDH1    IDH2    CD33    SMO | FLT3 antagonist    IDH1 antagonist    IDH2 antagonist    CD33 antagonist    SMO antagonist | midostaurin, gilteritinib    ivosidenib    enasidenib    gemtuzumab ozogamicin    glasdegib |
| Multiple myeloma (MML) | Proteasome    CD38    SLAMF7    BCMA    CRM1    --- | Proteasome inhibitor    CD38 antagonist    SLAMF7 antagonist    BCMA antagonist    CRM1 antagonist    --- | bortezomib, carfilzomib, ixazomib    daratumumab, isatuximab-irfc    elotuzumab    belantamab mafodotin    selinexor    lenalidomide, pomalidomide |